Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

Current factor VIII (FVIII) products display a half-life (t(1/2)) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single molecule of FVIII covalently linked to the Fc domain...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Powell, Jerry S., Josephson, Neil C., Quon, Doris, Ragni, Margaret V., Cheng, Gregory, Li, Ella, Jiang, Haiyan, Li, Lian, Dumont, Jennifer A., Goyal, Jaya, Zhang, Xin, Sommer, Jurg, McCue, Justin, Barbetti, Margaret, Luk, Alvin, Pierce, Glenn F.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2012
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646317/
https://ncbi.nlm.nih.gov/pubmed/22223821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-09-382846
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items